5Giuseppe M, Guy DB, Anna D, et al. 2007 Guidelines for the management of arterial hypertension. ESI-I/ESC [ J ]. J Hypertens, 2007,25 : 1105 - 1187.
6Zanchetta A, Hansson L, Dahlof B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Hot study group[J]. J Hypertens, 2001,19:1149 -1159.
7Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsatan or amlodipine: the VALUA randomized trail[ J ]. Lancet, 2004, 363:2022 - 2031.
8Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOTBPLA) : a muhicentre randomized controlled trial[ J ]. Lancet, 2005,366:895 - 906.
